N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Plasma Exchange in Pediatric Autoimmune Encephalitis

Sponsor: Menoufia University • ClinicalTrials.gov ID: NCT07707739

Registry updated: 2026-10-07
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The aim of the study will be to compare the efficacy of daily plasma exchange (PLEX) versus alternate-day PLEX in achieving a favorable functional outcome in children with autoimmune encephalitis. The study population will be divided into two groups, the first group will perform PLEX on consecutive days and the second one will perform it every other day. Then, A Favorable functional outcome measure defined as modified Rankin Scale (mRS) score ≤ 2. The mRS will be assessed by a blinded assessor at the end of the sessions to determine which method has superior efficacy in treatment of autoimmune encephalitis.

Interventions

  • Plasma exchange (PE) (Procedure)
    Plasma exchange (PE) sessions to be done daily for Arm A
  • Plasma exchange (PE) (Procedure)
    Plasma exchange (PE) sessions to be done on every other day for Arm B

Eligibility criteria

Inclusion Criteria: * Childern diagnosed as autoimmune encephalitis according to Cellucci et al., 2020; acute/subacute onset (\<3 months) of encephalopathy with at least one of: new focal CNS findings, seizures, CSF pleocytosis, MRI suggestive of encephalitis, and supportive antibody testing when available. * Autoimmune encephalitis cases indicated clinically for PLEX as determined by the treating team (e.g., severe disease, refractory to steroids/IVIG or as part of first-line combination therapy). Exclusion Criteria: * Hemodynamic instability not amenable to plasma exchange. * Severe coagulopathy uncorrectable prior to PLEX (INR \>2 despite correction, platelets \<50,000/µL unless corrected). * Contraindications to central venous access placement. * Enrollment in another interventional trial that would interfere with the outcomes.

Conditions

Autoimmune Encephalitis (AE)

Locations

  • Menoufia university hospital, Pediatric intensive care unit — Shibīn al Kawm, Menoufia Governorate, Egypt
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record